Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells

Tao Zhang, Haojie Lu, Weijun Li, Ronggui Hu, Zi ChenInternational Journal of Molecular Sciences 2015 · DOI

TL;DR

Arsenic trioxide (As₂O₃) is a potent treatment for acute promyelocytic leukemia (APL), but its precise molecular targets remain elusive. This study identifies over 40 proteins in APL cells that directly bind arsenic, with a particular focus on pyruvate kinase M2 (PKM2). The findings suggest that PKM2's interaction with arsenic is a key mechanism underlying As₂O₃'s therapeutic effects in APL.

What Problem Does This Paper Address?

Arsenic trioxide (As₂O₃) has revolutionized the treatment of acute promyelocytic leukemia (APL), a blood cancer characterized by a specific chromosomal translocation. While As₂O₃ is highly effective, its exact molecular mechanisms of action are not fully understood. Beyond its known effect of degrading the PML-RARα fusion protein, it's hypothesized that As₂O₃ might exert its therapeutic effects by directly interacting with other cellular proteins. Identifying these direct arsenic-binding proteins is crucial for a comprehensive understanding of As₂O₃'s anti-leukemic activity and for developing more targeted therapies. The challenge lies in pinpointing these specific protein interactions within the complex cellular environment.

Methods

The researchers employed a multi-pronged approach:

  • Arsenic-Biotin Conjugate Synthesis: They synthesized biotinylated arsenic compounds (biotin-As I and biotin-As II) to serve as probes for capturing arsenic-binding proteins.
  • Cell Viability Assay (MTT): They used the MTT assay to assess the impact of As₂O₃ and the arsenic-biotin conjugates on the proliferation of NB4 APL cells, determining IC₅₀ values to establish the efficacy of their probes.
  • Affinity Pull-down and LC-MS/MS: This was the core identification strategy. NB4 cells were treated with arsenic-biotin conjugates, and then proteins that bound to the arsenic were "pulled down" using streptavidin. The eluted proteins were then analyzed using liquid chromatography-mass spectrometry (LC-MS/MS) to identify them.
  • Western Blot: Used to confirm the presence of arsenic-binding proteins in the pull-down fractions.
  • In Vitro Binding Assays: To validate the direct interaction of specific candidate proteins (GSTP1, PKM2, and HSPA9) with arsenic, recombinant proteins were tested in binding assays using His and biotin antibodies.
  • Enzyme Activity Assay: The activity of pyruvate kinase M2 (PKM2) was measured in NB4 cells treated with arsenic-biotin to assess the functional impact of arsenic binding.

Datasets

Not discussed in the paper. The study utilized NB4 human APL cells as the biological system for their experiments.

Key Insights and Ideas

  • Arsenic has a broad range of direct protein targets in APL cells: The study identified over 40 proteins that directly bind to arsenic, suggesting that As₂O₃'s action is not limited to a single target.
  • Cysteine residues are key for arsenic binding: The paper reinforces the established understanding that vicinal (closely spaced) cysteine residues in proteins are critical for arsenic binding.
  • Pyruvate Kinase M2 (PKM2) emerges as a significant arsenic binder: Among the identified proteins, PKM2 showed a particularly high affinity for arsenic in vitro. This finding is significant because PKM2 is known to play a role in cancer metabolism and proliferation.
  • PKM2 activity is suppressed by arsenic: The study demonstrated that arsenic-biotin treatment significantly reduced PKM2 activity in NB4 cells, suggesting a functional consequence of arsenic binding.
  • GSTP1 and HSPA9 do not directly bind arsenic in vitro: While identified as potential arsenic binders, further in vitro assays showed that GSTP1 and HSPA9 did not directly interact with arsenic, suggesting their roles might be indirect or that the in vivo binding conditions differ.

Key Results

  • Over 40 arsenic-binding proteins identified: Using LC-MS/MS, the researchers identified a substantial number of proteins that directly bind to arsenic in NB4 APL cells. These proteins were categorized into functional groups like redox-related proteins, transcription factors, and cell cycle regulators.
  • PKM2 exhibits high affinity for arsenic: In vitro binding assays confirmed that PKM2 directly binds to arsenic with high affinity.
  • Arsenic-biotin inhibits PKM2 activity: Treatment of NB4 cells with arsenic-biotin led to a significant reduction (67%) in PKM2 activity.
  • Biotin-As I was more potent than As₂O₃: The arsenic-biotin conjugate, biotin-As I, showed a greater inhibitory effect on NB4 cell growth compared to As₂O₃ itself, suggesting biotinylation might enhance arsenic's cellular uptake or binding.

Limitations and Future Work

  • In vitro vs. in vivo binding: While the study identified potential arsenic-binding proteins, the in vitro binding assays for GSTP1 and HSPA9 yielded negative results, highlighting the complexity of protein-arsenic interactions in a cellular context. Further investigation is needed to reconcile these findings.
  • Mechanism of PKM2 suppression: The paper demonstrates that arsenic-biotin suppresses PKM2 activity but does not fully elucidate the precise molecular mechanism of this suppression.
  • Broader implications of other identified proteins: The study focused on a few key proteins, but the roles of the other 40+ identified arsenic-binding proteins in APL pathogenesis and As₂O₃ treatment remain to be explored.
  • Future Directions: The authors suggest that further investigation into the specific signaling pathways through which PKM2 mediates APL development, and how arsenic interacts with these pathways, could lead to a better understanding of arsenic's effects on APL. Exploring the functional consequences of arsenic binding to other identified proteins is also a promising avenue.

Summary updated

Abstract

The identification of arsenic direct-binding proteins is essential for determining the mechanism by which arsenic trioxide achieves its chemotherapeutic effects. At least two cysteines close together in the amino acid sequence are crucial to the binding of arsenic and essential to the identification of arsenic-binding proteins. In the present study, arsenic binding proteins were pulled down with streptavidin and identified using a liquid chromatograph-mass spectrometer (LC-MS/MS). More than 40 arsenic-binding proteins were separated, and redox-related proteins, glutathione S-transferase P1 (GSTP1), heat shock 70 kDa protein 9 (HSPA9) and pyruvate kinase M2 (PKM2), were further studied using binding assays in vitro. Notably, PKM2 has a high affinity for arsenic. In contrast to PKM2, GSTP1and HSPA9 did not combine with arsenic directly in vitro. These observations suggest that arsenic-mediated acute promyelocytic leukaemia (APL) suppressive effects involve PKM2. In summary, we identified several arsenic binding proteins in APL cells and investigated the therapeutic mechanisms of arsenic trioxide for APL. Further investigation into specific signal pathways by which PKM2 mediates APL developments may lead to a better understanding of arsenic effects on APL.
BibTeX
@article{zhang2015identification,
  author = {Tao Zhang and Haojie Lu and Weijun Li and Ronggui Hu and Zi Chen},
  title = {{Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells}},
  journal = {International Journal of Molecular Sciences},
  year = {2015},
  doi = {10.3390/ijms161125994},
}
Figure